[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE327245T1 - Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren - Google Patents

Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren

Info

Publication number
ATE327245T1
ATE327245T1 AT98937049T AT98937049T ATE327245T1 AT E327245 T1 ATE327245 T1 AT E327245T1 AT 98937049 T AT98937049 T AT 98937049T AT 98937049 T AT98937049 T AT 98937049T AT E327245 T1 ATE327245 T1 AT E327245T1
Authority
AT
Austria
Prior art keywords
leukocytes
amino
compounds containing
mediated adhesion
phenylalanine group
Prior art date
Application number
AT98937049T
Other languages
English (en)
Inventor
Susan Ashwell
Francine S Grant
Andrei W Konradi
Anthony Kreft
Louis John Lombardo
Michael A Pleiss
Dimitrios Sarantakis
Christopher M Semko
Eugene D Thorsett
Original Assignee
Elan Pharm Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Wyeth Corp filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE327245T1 publication Critical patent/ATE327245T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT98937049T 1997-07-31 1998-07-30 Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren ATE327245T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92035397A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
ATE327245T1 true ATE327245T1 (de) 2006-06-15

Family

ID=25443597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937049T ATE327245T1 (de) 1997-07-31 1998-07-30 Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren

Country Status (17)

Country Link
EP (1) EP1001974B1 (de)
JP (1) JP2003517424A (de)
KR (1) KR20010022414A (de)
CN (1) CN1265674A (de)
AR (1) AR014903A1 (de)
AT (1) ATE327245T1 (de)
AU (1) AU8584698A (de)
BR (1) BR9812118A (de)
CA (1) CA2290750A1 (de)
DE (1) DE69834642T2 (de)
HU (1) HUP0004531A3 (de)
IL (1) IL133638A0 (de)
NO (1) NO20000411L (de)
NZ (1) NZ502580A (de)
PL (1) PL338413A1 (de)
WO (1) WO1999006434A1 (de)
ZA (1) ZA986837B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
AU7667498A (en) * 1997-05-30 1998-12-30 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
JP2001517246A (ja) 1997-06-23 2001-10-02 田辺製薬株式会社 α▲下4▼β▲下1▼媒介細胞接着の阻止剤
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU3260399A (en) 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
PL343770A1 (en) 1998-04-16 2001-09-10 Texas Biotechnology Corp N,n-disubstituted amides that inhibit the binding of integrins to their receptors
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
NZ513254A (en) * 1999-02-18 2003-10-31 F Thioamide derivatives
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6630503B1 (en) * 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
IL149758A0 (en) 1999-12-28 2002-11-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
EP1301488A1 (de) 2000-07-07 2003-04-16 Celltech R&D Limited Bicyclische heteroaromatische ring enthaltende quadratsäure-derivate als integrin-antagonisten
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20050069541A1 (en) * 2003-01-24 2005-03-31 Karlik Stephen J. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20060154970A1 (en) * 2003-01-28 2006-07-13 Yushe Yang Alanines compounds, method of preparing them and their use
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
KR100646882B1 (ko) * 2004-08-09 2006-11-23 엘지전자 주식회사 전기오븐레인지의 오븐부 배기구조
EP2364705A3 (de) 2004-08-19 2012-04-04 Vertex Pharmaceuticals Incorporated Modulatoren von muskarinischen Rezeptoren
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
NZ555444A (en) 2004-11-29 2011-01-28 Vertex Pharma Modulators of muscarinic receptors
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008005295A2 (en) 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101573121A (zh) 2006-08-18 2009-11-04 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP2124996A4 (de) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Verfahren zur behandlung von multipler sklerose mittels verabreichung eines alpha-fetoproteins in kombination mit einem integrinantagonisten
JP2010540640A (ja) 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン作用性レセプターのモジュレーター
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
DE102009058289A1 (de) 2009-12-04 2011-06-09 Vladimir Volchkov Viertaktmotor und Verfahren zu seinem Betrieb
DE102009058290A1 (de) 2009-12-04 2011-06-09 Vladimir Volchkov Viertaktmotor, Verfahren zu seinem Betrieb und Kraftstoffeinspritzverfahren
DE102010008225A1 (de) 2010-02-09 2011-08-11 Volchkov, Vladimir, 71638 Viertakt-Gegenkolbenmotor und Verfahren zu seinem Betrieb
CA3116769C (en) 2018-10-30 2023-08-22 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria

Also Published As

Publication number Publication date
IL133638A0 (en) 2001-04-30
NO20000411D0 (no) 2000-01-27
HUP0004531A3 (en) 2001-12-28
CN1265674A (zh) 2000-09-06
EP1001974B1 (de) 2006-05-24
ZA986837B (en) 2000-05-02
HUP0004531A2 (hu) 2001-04-28
AU8584698A (en) 1999-02-22
BR9812118A (pt) 2000-07-18
DE69834642D1 (de) 2006-06-29
EP1001974A1 (de) 2000-05-24
KR20010022414A (ko) 2001-03-15
NZ502580A (en) 2001-06-29
DE69834642T2 (de) 2007-05-03
JP2003517424A (ja) 2003-05-27
CA2290750A1 (en) 1999-02-11
NO20000411L (no) 2000-03-28
PL338413A1 (en) 2000-11-06
AR014903A1 (es) 2001-04-11
WO1999006434A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
ATE327245T1 (de) Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren
DE60036918D1 (de) Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
ZA986834B (en) Compounds which inhibit leukocyte adhesion mediated by VLA-4.
IL133641A0 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986827B (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
NO20000414D0 (no) Benzylforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
IL133636A0 (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
IL133637A0 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
AR244740A1 (es) Una composicion de polipropileno.
DE69520347D1 (de) Borsäure-Verbindungen mit einer Binaphthyl-Gruppe
FI971674A0 (fi) Heterosyklisen ryhmän sisältämät di-tert-butyyli-fenoliyhdisteet, käyttökelpoisia tulehduksenvastaisina aineina
NO961074D0 (no) Fremgangsmåte for rensing av en xantofyllforbindelse
ATE240645T1 (de) Neue fungizide mischung, die ein 2-imidazolin-5- one enthält
FR2725899B1 (fr) Composition contenant un precurseur de la dihydroxyacetone
FR2692479B1 (fr) Composition dentaire polymérique contenant un composé métallique.
DE69601560D1 (de) Polypropylen-Harzmasse
PT806949E (pt) Nova composicao farmaceutica contendo trimebutina e seu processo de preparacao
FR2771116B1 (fr) Procede d'assemblage de parpaings servant a la construction de murs porteurs
DE68907157D1 (de) Beta-lactam-synthese mit hilfe einer metallverbindung als katalysator.
IT1278088B1 (it) Procedimento per la produzione di stampa a riserva.
FR2730601B1 (fr) Machine a retourner les andains, notamment de fumier
ES296168Y (es) Fachadas conformadas por revestimiento a partir de placas modulares.
ZA986830B (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4.
ATE90684T1 (de) Beta-lactam-synthese mit hilfe einer metallverbindung als katalysator.
FI944414A (fi) N-t-butyyli-androst-3,5-dieeni-17B-karboksamidi-3-karboksyylihapon polymorfi A

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties